MAPS/Lykos’ MDMA trials for PTSD delivered overwhelmingly positive results. I thought that mattered until I sat through a nine-hour deliberation among the FDA’s Psychopharmacologic Drugs Advisory Committee on June 4, including two hours of public comments that skewed anti-Lykos. After a long day of groupthink, the panel advised the FDA that MDMA therapy was neither […]
The post When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA appeared first on Psychedelics Today.
